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Multiparticulate systems have biopharmaceutical advantages when compared to the monolithic systems, 
once they allow different patterns of drug release and can be used in different treatments. The aim 
of the present work was to develop a biphasic controlled release delivery system, using propranolol 
hydrochloride (PROP) that can be used for the treatment of circadian diseases. This system was obtained 
by the combination of cellulosic polymers hydroxypropyl methylcellulose (HPMC) and ethylcellulose 
(EC) in a 2² factorial experimental design, which allowed the optimization of the development stage. 
The pellets produced and used in biphasic formulations were evaluated for physical and chemical 
characteristics and presented acceptable results. The immediate fraction obtained showed the complete 
release in 30 min while the others kept the release of the drug for 24 h. This study showed that the 
combination of beads with different releasing characteristics allowed to obtain different release profiles, 
which can be modulated according to the pathological needs, especially with regard to circadian diseases 
that suffer alterations throughout the day.
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INTRODUCTION
Multiparticulate systems are, by definition, a 
functional unit that contains the drug subdivided into 
pellets, granules, mini-pills or a combination of these 
(Zerbini, Ferraz, 2011). Pellets are spherical units 
constituted by agglomeration of drugs and excipients, with 
diameters ranging from 100 to 2000 µm, and may act as 
an intermediate for the production of sachets, capsules or 
tablets. Multiparticulate systems have advantages when 
compared to classical unitary systems: better distribution 
on the gastrointestinal tract (GIT), lack of influence of 
gastric emptying, lower risk of systemic toxicity and local 
irritation, as well to enable the obtaining of customized 
release forms (Ghebre-Selassie, 1989; Bauer et al., 
1998; Pezzini, Silva, Ferraz, 2007; Aulton, Ortega, 2008; 
Kulkarni, 2010; Lachman, Lieberman, Kaning, 2013).
In an ideal therapeutic regimen, the drug must reach 
the site of action quickly and its release must be constant 
during the treatment. Some drugs have naturally a long 
time of action, requiring only one daily dosing to maintain 
the adequate plasma levels. However, many others must be 
administered repeatedly, which may result in a seric drug 
fluctuation in intervals prior to the next administration 
(Aulton, Ortega, 2008; Bruschi, 2015). As an alternative 
to such inconvenience, it has been increasingly sought 
the use of systems capable of modulating the release 
of the drug in a gradual manner, providing a reduction 
in the frequency of administration, less fluctuation in 
plasma concentrations of the drug, less side effects and 
greater adherence to treatment (Lopes, Lobo, Costa, 2005; 
Villanova, Oréfice, Cunha, 2010).
On the types of modified release existing in the 
pharmaceutical context, the biphasic delivery system 
stands out, which is intended to release the drug at different 
stages of release, a fraction of initial release (fast) and 
a modified release (slow) and the first fraction may be 
represented by the immediate release, while the second by 
extended release (Jha, Rahman, Rahman, 2011). 
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Representing the pharmacotherapeutic agent 
candidates and attractive for this type of release, one has 
the antihypertensive drugs, antihistamines, analgesics, 
antipyretics and anti-allergic. These drugs are used 
for the treatment of diseases known as circadian that 
have oscillations according to the period of the day, 
since the human organism is complex and is constantly 
subject to physiological and biochemical changes, such 
as the case of hypertension, where the occurrence of 
manifestations related to cardiovascular complications 
occur predominantly in the early morning hours, period 
on which the blood pressure is higher (Londhe, Gattani, 
Surana, 2010; Ohdo, 2010; Jha, Rahman, Rahman, 2011; 
Lin, Kawashima, 2012; Verdecchia et al., 2012; Dallmann, 
Brown, Gachon, 2014).
To obtain a specific release system, it is often 
necessary the use of polymer-based coatings, being 
common in these cases the mixture of polymers with 
different characteristics and solubility properties, 
for example the association of cellulose derivatives 
hydroxypropyl methylcellulose (HPMC), with high water 
solubility, and ethyl cellulose (EC), with water-insoluble 
characteristics, widely used in pharmaceuticals in order 
to obtain modified drug release systems (Lopes, Lobo, 
Costa, 2005; Oliveira, 2007; Guerra-Ponce et al., 2016).
In cases in which are used the combination of 
polymers to obtain the desired release profile, it is 
extremely important the knowledge of its characteristics 
and influence in the formulation, in order to reduce the 
development time and the number of trials. Thus, several 
tools have been used to optimize the development phase, 
as the case of the use of the experimental design tool 
that provides more accurate information with a lower 
number of experiments. In the present scenario, the 
pharmaceutical industry seeks to increasingly reduce the 
development time and getting more robust processes that 
increase competitiveness in the market (Pisano, 1997; 
Singh, Kumar, Ahuja, 2005; Rubin et al., 2006; Lachman, 
Lieberman, Kaning, 2013).
The aim of the present study was to develop a 
biphasic controlled release delivery system with length 
of 24 hours, for the treatment of circadian diseases, 
using propranolol hydrochloride (PROP), a β-blocker 
drug widely used in heart diseases. Due to the peak 
concentration of 1-1.5 hour and the half-life of 4-6 hour, 
the active may be considered a strong candidate for 
developing a modified-release formulation (Brasil, 
2010b). For that, it was used a combination of cellulosic 
polymers for coating with HPMC-EC polymers associated 
with a 2² factorial experimental design to the optimization 
of the development stage.
MATERIAL AND METHODS
Material
Propranolol hydrochloride, (PROP) (Iffect 
Chempar Co. Ltda, India), polyvinylpyrrolidone 
K30 –Plasdone® K30, (PVP K30) (Ashland, USA); 
sucrose inert beads 25-30 mesh, (EIS) (JRS Pharma, 
Germany); ethylcellulose N45 –Ethocel® N45 (EC) and 
hydroxypropyl methylcellulose 5cps –Methocel® E5 
LV, (HPMC) (Colorcon, USA); talc (Magnesita, Brasil) 
and Triethyl citrate (TEC) (Vertelus, USA). The raw 
materials and excipients used were kindly provided by 
Prati Donaduzzi Ltda Pharmaceutical Industry, Brazil.
Compatibility study
The interaction between the drug and the excipients 
were evaluated through analysis of Differential Scanning 
Calorimetry (DSC) and Fourier Transform Infrared 
Spectroscopy (FTIR). Analyses were performed on 
samples containing pure PROP, binary mixtures of PROP 
with excipients in the proportion 1:1, mixture of the 
placebo used in the final formulation and PROP in equal 
proportion (1:1) and also the pellets of the best formulation 
obtained at the end of the development stage. 
DSC analyses were performed using a DSC-1 
(Mettler Toledo) and the results were processed in Star® 
software, licensed by Mettler-Toledo®. The analyses 
of FTIR were performed by using a Infrared Fourier 
Transform Spectrophotometer (Spectrum 400®, Perkin 
–Elmer®) with accessory of attenuated total reflectance 
probe (ATR) to mid-infrared.
Development of the immediate release fraction
For choosing the bonding agent employed in 
the attainment of pellets 4 formulations (A - D) were 
prepared using the solution PVP K30 or HPMC polymers 
in different proportions. An initial loading of 1500 g of 
EIS was used in the preparation of the formulations. The 
composition of formulations are shown in Table I. 
For formulation A, the EIS was coated with an 
alcohol solution, a mixture of PROP, PVP K30 and talc. 
For the formulations B, C and D, EIS were coated with a 
hydroalcoholic solution (1:1, w/w) containing the mixture 
of PROP, HPMC and talc. The coating process of all 
formulations were performed in fluidized bed (Bosch 
Hüttlin® Unilab®), following the parameters: Inlet air 
flow rate = 250 m³/h, inlet air temperature = 40 – 45 °C and 
product temperature = 37 – 39 °C. After completion of the 
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coating process, the pellets were dried at 40 °C for 30 min.
The yield (R%) of the formulations was calculated 
as:
 (1)
From the initial formulations, the one with the 
highest yield and performance was used for developing the 
pellets. The formulation chosen, initial weight of 1500 g of 
pellets coated with PROP, was subjected to seal coating, 
prepared from an aqueous colloidal dispersion of HPMC 
(8.20%, w/w). The following parameters were followed: 
Inlet air flow rate = 250 m³/h, inlet air temperature = 45–50 
°C, product temperature = 39–41 °C, atomization pressure 
= 1.20 bar, microclimate pressure = 0.25 bar, atomization 
nozzle diameter = 1.0 mm, air cap diameter = 12 mm, 
and atomization rate of the coating suspension = 10-14 g/
min. After the coating process, the pellets were dried for 
30 min at 40 °C. 
Development of the modified release fraction
To optimize the development of PROP pellets for 
modified release, experiments were performed based on 
a full factorial design with two factors in two levels (2²) 
and triplicate on the center point, resulting in 7 modified 
release formulations. The variables studied were the 
concentrations of HPMC and EC coating polymers in the 
third coating layer of the pellets as well as HPMC x EC 
interaction in response of the PROP release time. For each 
factor (HPMC and EC), two levels were used: -1 (low) and 
+1 (high), according to Table II.
The experiments were performed randomly and with 
triplicate at the center point. The factorial matrix used 
for the design of experiments is shown in Table III. The 
experimental data obtained from this 22 factorial design 
were processed using the Design Expert® 7.1.3 software. 
The significance of the factors and model validation were 
confirmed by the analysis of variance (ANOVA) and linear 
regression.
In order to obtain modified release pellets, it was 
used as starting point PROP pellets with seal coating, 
an initial amount of 1500 g for batches. The coating 
of the F1 to F7 formulations was carried out from a 
hydroalcoholic solution (ethanol: water 9:1 w/w) of the 
EC, HPMC and TEC mixture, as the amounts described 
in Table IV. The following parameters were followed: 
inlet air flow rate = 250 m³/h, inlet air temperature = 
40–45 °C and product temperature = 35–37 °C. After 
completion of the coating process, the pellets were dried 
at 40 °C for 30 min.
Obtaining the multiparticulate biphasic system of 
PROP
Different proportions of the immediate and modified 
release pellets obtained were placed in hard gelatin capsules 
#1 for evaluation and comparison of the dissolution 
profiles, resulting in the F8 and F9 formulations. The final 
concentration of 80 mg PROP was maintained in each of 
the formulations.
TABLE I - Composition of formulations for choosing bonding 
agent
Composition A (%) B (%) C (%) D (%)
PROP 11.32 11.32 11.32 11.32
PVP K30 1.89 - - -
HPMC - 0.94 2.83 3.77
Talc 2.83 2.83 2.83 2.83
EIS 29.25 30.19 28.30 27.36
Isopropyl Alcohol 
(AIS)
54.72 27.36 27.36 27.36
Purified Water - 27.36 27.36 27.36
Total 100.00 100.00 100.00 100.00
TABLE II - HPMC and EC variables and levels (-1, 0 and 1) used 
in the factorial experimental design 2²
Variables
Levels
-1 0 1
HPMC (mg) 2.00 4.00 6.00
EC (mg) 10.00 20.00 30.00
TABLE III - Factorial 2² planning for the codified variables: 
HPMC (mg) and EC (mg). Experiments performed randomly 
and with triplicate at the center point
Formulation Sequence
Variables codified
HPMC (mg) EC (mg)
F1 4 -1 -1
F2 3 1 -1
F3 5 -1 1
F4 2 1 1
F5 6 0 0
F6 1 0 0
F7 7 0 0
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Determination of drug content
PROP content in the pellets was determined using 
a UV/Vis spectrophotometer (Varian Cary® 50). A pellet 
mass equivalent to 25 mg PROP was weighed and 
transferred to a 25 mL volumetric flask, added with 2 
mL methanol and the flask was taken to ultrasonic bath 
(Unique, model C3300) for 40 min. Subsequently, more 
12.5 mL methanol was added and the flask was taken 
to ultrasonic bath for another 20 min. The volumetric 
flask volume was filled with the same solvent. From this 
solution, an aliquot of 2.0 mL was transferred to a 25 mL 
volumetric flask and the volume was completed with HCl 
0.01 N. All solutions were filtered through a quantitative 
cellulose filter and the final concentration was 0.08 mg/
mL PROP. The samples were analyzed by UV/VIS 
spectrophotometer at 289 nm and trials were performed 
in triplicate.
Dissolution profile
Dissolution of PROP pellets was performed by a 
methodology validated in our laboratory according to 
Resolution n. 899 of ANVISA (Brasil, 2003), in USP 
dissolutor apparatus 1 (basket) Sotax® Semiautomatic, 
coupled to the automatic samples collector, using 
hydrochloric acid solution (HCl 0.01 N, 1000 mL) as 
dissolution medium at 37.0 ± 0.5 °C. The collections and 
respective readings occurred on-line at time intervals of 
5, 10, 15, 20, 30, 60 and 90 min for the pellets with active 
coating and sealing coating and at intervals of 30, 60, 90 
, 120, 180, 240, 360, 480, 600, 720, 960, 1200 and 1440 
min for the modified pellets of biphasic release. For F3 
the analysis time has been extended to 2400 min. Samples 
were analyzed by spectrophotometry in the ultraviolet 
region at 289 nm using UV/Vis spectrophotometer to 
determine the concentration of drug present.
The dissolution efficiency (DE) was calculated by 
the method described by Khan (1975) and the similarity 
factor (f2) was evaluated in order to compare the similarity 
between the percentage of drug dissolved among the 
formulations, according to Costa, Lobo (2001); Maggio, 
Castellano, Kaufman (2008), where the dissolution of 
a number of samples (n) of reference (Rt) and test (Tt) 
products are compared in a certain period of time:
 (2)
For the dissolution curves to be considered similar, 
the f2 value should be between 50 and 100 (Brasil, 2010a).
Characterization of the pellets obtained
Pellets that presented the desired release properties 
to obtain the biphasic formulations of PROP were 
analyzed for granulometric evaluation, apparent (AD) 
and compacted (CD) density, friability, loss by drying, 
sphericity and evaluation of the external morphology.
For the granulometric evaluation, 100.0 g samples 
were subjected to the vibrational agitation of 15 Hz for 
10 min in a sieve Impact Test Sieve Shaker SV001, using 
18, 20, 25, 30 and 35 mesh. The results were expressed in 
percentage of pellet mass retained in each mesh.
The evaluation of the pellet density was obtained 
after evaluation of a sample of 50 g in 250 mL graduated 
measuring cylinder, subjected to 200 beats, with the aid of 
a compaction densimeter Pharma Test PT-TD200 (Mehta 
et al., 2012). The friability (%F) was determined according 
to European Pharmacopoeia (2011), by weighing the mass 
loss after 960 horizontal oscillations (240 oscilations per 
minute for 4 min) and determined according to equation 
(3) (Mehta et al., 2012):
  (3)
TABLE IV - Formulation for obtaining modified release pellets
Composition F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg)
Pellets Sealed 337.60 337.60 337.60 337.60 337.60 337.60 337.60
EC 10.00 10.00 30.00 30.00 20.00 20.00 20.00
HPMC 2.00 6.00 2.00 6.00 4.00 4.00 4.00
TEC 1.20 1.60 3.20 3.60 2.40 2.40 2.40
Alcohol 96 ºGL* 682 682 682 682 682 682 682
Purified Water* 68.20 68.20 68.20 68.20 68.20 68.20 68.20
Total 350.80 355.20 372.80 377.20 364.00 364.00 364.00
* Solvent evaporates during the process.
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The moisture content (n=3) was determined in 
an infrared moisture balance (Mettler-Toledo® HB43-S 
Halogen), weighing samples of 2.0 g at the maximum 
temperature of 105 °C till constant mass. The percentage 
referring to the weight loss was considered as the moisture 
content of the sample.
Sphericity (S) of the pellets was calculated according 
to Lovgren and Lundberg (1989), through measurement 
of the length and width of the bidimensional image of 
the pellets using 20 units. The format was expressed as 
a sphericity percentage, where 100% corresponds to a 
perfect circle. 
The evaluation of the external morphology of the 
pellets was performed through images obtained by scanning 
electron microscopy (SEM) (Shimadzu®, SS 550 model), 
at accelerating voltage of 15.0 kV and probe current of 4.0 
pA. Samples were placed in a metallic sample holder, fixed 
with carbon tape, and subsequently coated with a thin layer 
of gold, using a current of 4 mA for 3 min. 
RESULTS AND DISCUSSION
The study of compatibility between the active and 
the excipients is of fundamental importance, since it 
can reduce or predict possible complications during the 
development of the drug (Aulton, Ortega, 2008).
The DSC curves obtained for the PROP and the 
binary mixtures are showed in Figure 1. The thermogram 
obtained for the PROP showed a pronounced endothermic 
peak at 163.73 °C characteristic of its melting point 
(Sahoo et al., 2008; Farmacopeia Brasileira, 2010). The 
thermograms obtained from the binary mixtures between 
excipients and PROP showed no significant alterations 
of the endothermic peak, indicating a good compatibility 
between the PROP and the chosen excipients. Samples of 
the placebo and PROP mixture and the final formulation of 
PROP also showed no alterations of these peaks, indicating 
that even after the use of excipients and the preparation 
process, the characteristics of the drug remained unaltered. 
FIGURE 1 - Thermal analysis of DSC A) Final formulation of PROP; B) PROP + Placebo of the pellets; C) PROP + talc; D) PROP 
+ PVP K30; E) PROP + HPMC; F) PROP + EIS; G) PROP.
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Although the DSC analysis is the most used in 
compatibility studies, the interpretation of data provided 
are not always easy and can lead to misinterpretation of 
results. Moreover, the results obtained at high temperatures 
may not be relevant when it comes to room and/or storage 
temperature being often advisable to use confirmatory 
techniques, such as FTIR (Liltorp et al., 2011; Tiţa et al., 
2011). The results obtained in FTIR analysis are shown 
in Figure 2. Pure propranolol showed characteristic 
peaks between 3650-3200 cm-1 (-OH stretch), 3500-3100 
cm-1 (N-H stretch), 3100-3000 cm-1 (styrene -CH of 
aromatics), 1600-1475 cm-1 (aryl C=C stretch), 1240 and 
1030 cm-1 asymmetric and symmetrical O-CH2 stretches, 
respectively, and at 798 cm-1 due to alpha-substituted 
naphthalene. Peaks corresponding to pure propranolol in 
final formulation confirm the absence of interaction among 
samples analyzed, since no significant alterations are 
observed (Srikanth et al., 2012; Saeedi, Morteza-Semnani, 
Sagheb-Doust, 2013).
Tests from A to D, as described in Table 4, were 
performed in order to define the most suitable bonding 
agent in the attainment of immediate release pellets. After 
obtaining formulation A, it was observed a yield of 85.7% 
and 86.0% PROP content of the pellets, with the presence 
of many pellets agglomerated and fine powder inside the 
equipment during the process, suggesting that the increase 
in bonding agent, PVPK 30, in the attempt to correct 
the loss of powder, would worsen the agglomeration of 
the pellets while its decrease would cause the increase 
of powder loss. For the formulation B, it was obtained 
94.20% yield and PROP content of 84.40%, in this case, 
it was possible to observe a considerable loss of the active 
FIGURE 2 - Infrared absorption spectrum A) PROP; B) PROP+EIS; C) PROP + HPMC; D) PROP + PVP K30; E) PROP + Talc; 
F) PROP + Placebo; G) Final formulation of PROP.
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compound, which was confirmed with the presence of 
large amounts of fine powder inside the fluidized bed. 
Even obtaining a yield above 90.00% in the test, the PROP 
content was lower than expected.
In the attempt to solve the problem of powder loss 
during the coating process of B, C and D, tests were made 
with increasing amount of the HPMC bonding agent to 
2.83 and 3.77% respectively. In test C, it was obtained 
98.70% yield and 99.20% content of PROP, while in 
D, 92.10% yield, and 98.90% content of PROP. Even 
with the high content presented in the two formulations, 
formulation D presented lower yield when compared to C. 
This is possibly because the high concentration of polymer 
applied may have favored the agglomeration of the pellets 
during the coating step. Thus, formulation C was selected 
for following the experiments, due to the best results in 
the requisites of yield and PROP content values within 
the expected. The results of yield and content of PROP 
are listed in Table V.
To prevent contact of the drug present in the active 
coating with the functional coating, a sealing coating layer 
was applied onto the active coating pellets (C), originating 
C1 in order to form a barrier between these two coatings 
and thus preventing the migration of the active compound 
to the functional coating and possible problems in the 
release and stability of the drug (McGinity, Felton, 2008). 
Besides protection against degradation, this coating allows 
the correction of defects and/or roughnesses that may 
exist on the surface of the pellets, allowing the functional 
coating to be distributed uniformly over the entire surface 
of the pellets (Prasad et al., 2013).
The modified release pellets were obtained through 
application of the functional coating, composed of EC 
and HPMC over the pellets containing seal coating (C1), 
in order to obtain a 24-hour release profile (1440 min). 
EC is a polymer derived from cellulose, which has a good 
capacity to form transparent films, flexible and resistant, 
however water-insoluble, while HPMC has high solubility 
in water therefore being much used as pore former in 
modified release coatings (Rowe, Sheskey, Quinn, 2009).
TEC was used as a plast icizing agent  in a 
concentration of 10.00% in relation to the dry weight of the 
polymers, aiming to improve the flexibility characteristics 
of the film, to facilitate its distribution on the surface of 
the pellets and ensure homogeneity of the applied coating 
(Bauer et al., 1998).
For the evaluation of dissolution profile of the 
obtained pellets (Figure 3), it can be observed that C and 
C1 formulations showed an immediate release profile, 
since both formulations present average dissolution 
greater than 75.00% of the active substance within 30 min 
(Farmacopeia Brasileira, 2010), and the dissolution of C 
and C1, in 15 min, of 98.16% ± 1.13 and 94.90% ± 2.36, 
TABLE V - Results of yield and content of PROP found for the 
formulations from A to D
Formulation Yield (%) PROP content (%)
A 85.70 86.00
B 94.20 84.40
C 98.70 99.20
D 92.10 98.90
FIGURE 3 - Dissolution profiles of the pellets obtained in C and C1.
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respectively. However, even presenting an immediate 
release, the release profile of these formulations do not 
present similarity, since f2 =37.9.
The dissolution profiles obtained from the 
experimental design (Figure 4) show that F1 and F4 
formulations achieve respectively 100.10% and 101.93% 
of the active compound released within 960 min, showing 
a 16-hour releasing profile. F2 formulation reaches more 
than 95.00% of drug release within 30 min, releasing all 
the active compound loaded in up to 90 min, classifying C 
as well as C1 in the category of the immediate release. F3 
formulation releases only 84.20% of the amount of PROP 
present in the formulation in 1440 min, indicating that it 
would take more than 24 hours to release all PROP loaded 
in the pellets, representing a very slow release profile.
On the other hand, the profiles obtained by the 
formulations F5, F6 and F7 indicate a 24-hour release 
profile, reaching the PROP releasing aim during this 
period. Thus, formulation F5 was randomly chosen to 
represent the fraction of modified release of the biphasic 
formulation.
For the formulations F8 (20 mg C1 + 60 mg F5) 
and F9 (40 mg C1 + 40 mg F5), it was possible to obtain 
a biphasic release profile (Figure 5), so that F9 presented 
a faster release profile, when compared to F8 of up to 
about 600 min, extending the release in both formulations 
for a period of 24 hours. The dissolution efficiency (DE) 
values for F8 and F9 formulations were 75.94% ± 0.23 and 
83.04% ± 0.50, respectively, with f2 = 40. These results 
show that even with the two formulations presenting 
release profiles of 24 hours, there was no similarity 
between them and is still possible to obtain exclusive 
release profiles according to the pathological need by 
means of association of pharmaceutical units containing 
different kinetics of release.
Through the 2² factorial experimental design, it was 
possible to evaluate qualitatively and quantitatively the 
statistically significant factors that influence the total time 
of release of the drug (100%) in the dissolution profiles 
of the modified release PROP pellets. In the study, we 
evaluated the independent variables (HPMC and EC) 
and the interaction between these variables. The results 
obtained for the experimental design are listed in Table VI.
The highest value for the time of 100 % drug release 
was obtained with F3 with smaller amount of soluble 
polymer HPMC (2.00 mg) and greater amount of EC 
(30.00 mg), about 2400 min. This may be an indication 
that under these conditions few pores were formed by 
the soluble polymer HPMC against a great amount of 
insoluble polymer EC, delaying the release. The lowest 
value for the time of 100 % active compound release was 
obtained with formulation F2, with reverse condition, 
that is, a larger amount of HPMC (6.00 mg) and smaller 
amounts of EC (30.00 mg). In this condition, the insoluble 
polymer EC, by being in smaller concentrations, had no 
significant effect on the PROP release. For the intermediate 
FIGURE 4 - Dissolution profiles of the formulations obtained in the experimental design.
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conditions, the release was between 960 min (F4) and 
1440 min (F5, F6 and F7), this last being considered the 
optimum point of the study reaching 24 hours of release.
The significance of the factors and model validation 
were evaluated through analysis of variance (ANOVA). 
It was possible to observe that both factors, HPMC and 
EC were significant for a linear model (p < 0.05). The 
interaction between the variables and the curvature of 
the model were not significant (p> 0.05). The results of 
P-value <0.05 indicated that the model is valid at the 
significance level of 95%.
The value of R²=0.9705 is in accordance with the 
R²adj=0.9508, confirming this result. The linear model was 
constructed through the regression analysis, and describes 
the relationship between the significant independent 
variables and the response variable, as described below 
(equation 4), in which HPMC and EC are expressed in mg 
and the releasing time in minutes.
Realeasing time 100% = 1102.50 – [(288.75 x HPMC) + 
(57.75 x EC)]  (4)
The positive coefficient for the amount of EC and 
negative for HPMC means that a greater amount of EC 
increases the dissolution time to reach a release of 100%. 
On the other hand, a higher content of HPMC decreases this 
time. This is due to the solubility features of each polymer. 
The outline map and the response surface for 
the 100% releasing time is shown in Figures 6a and 
6b, respectively. There is no significant curvature, 
demonstrating that the linear model is valid.
The results obtained after the characterization 
analyses demonstrate that for the pellets used to obtain 
the biphasic formulations F8 and F9, both the AD and 
CD values are similar and that a percentage greater than 
90.00% of these same pellets were retained between the 
25-20 meshes (Table VII), evidencing good homogeneity 
of these parameters. All the samples presented moisture 
values lower than 5.00%, specification recommended 
by Mehta et al. (2012) and friability < 0.40%, indicating 
acceptable values according to the data present in the 
literature (Déo, Andreazza, Possamai , 2011). After the 
evaluation of the external morphology of the pellets 
(Figure 7), it was observed the smoothing of the C1 surface 
FIGURE 5 - F8 and F9 biphasic release profiles.
TABLE VI - Factorial experimental design 22 for the variables 
HPMC (mg) and EC (mg) with triplicate at the center point and 
release response time 100% (min) for the release profile of the 
pellets of modified release PROP
Formulation Sequence
Real Variables Release 
Time  
100% 
(min)
HPMC 
(mg)
EC 
(mg)
F1 4 2.00 10.00 960
F2 3 6.00 10.00 90
F3 5 2.00 30.00 2400
F4 2 6.00 30.00 960
F5 6 4.00 20.00 1440
F6 1 4.00 20.00 1440
F7 7 4.00 20.00 1440
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FIGURE 6 - Outline map A) and response surface B) for the experimental results of factorial experimental design 22. Response 
release time 100% (min) according to the amount of HPMC (mg) and EC (mg).
FIGURE 7 - Granulometric and external morphology analysis of pellets A) Granulometric analysis of the EIS and the pellets 
coated C, C1 and F5; B) Evaluation of the external morphology of the EIS in increase of 70x and 1000x; C) Evaluation of external 
morphology of C in increase of 70x and 1000x; D) External morphology evaluation of C1 in increase of 70x and 1000x; E) External 
morphology evaluation of F5 in increase of 70x and 1000x; F) Transversal image of F5 in increase of 1000x with emphasis in the 
coating layer of the pellet.
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after sealing coating when compared to the surfaces 
EIS and C and homogeneity of the polymeric coating 
performed in F5. 
Additionally, the thickness of the polymeric coating 
seems to be distributed uniformly throughout the surface 
of the pellet, which can be attributed to the good sphericity 
presented by the pellets (Table VII).
CONCLUSION
Thus, from our findings, it was possible to obtain a 
multiparticulate biphasic release system with the polymeric 
coating consisting of HPMC and EC, with quality within 
expected standards. The used 2² factorial experimental 
design allowed the optimization of the development stage, 
once it resulted in the 24-hour desired releasing profile 
with a small number of experiments. Furhtermore, it was 
observed that the biphasic formulations F8 and F9, which 
are a combination of different releasing forms, ensure 
different releasing profiles, allowing the therapeutic 
adjustment according to the pathological needs.
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